OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as President and Chief Executive Officer

OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as
President and Chief Executive Officer

(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer, announced that David (Dai) Chaplin, Ph.D., has
been appointed to the position of President and Chief Executive Officer,
replacing Peter Langecker, M.D., Ph.D.

Dr. Chaplin, a recognized international leader in pharmacology and tumor
biology, and a current member of OXiGENE's Board of Directors, brings
extensive experience in the fields of oncology research and cancer drug
development. Dr. Chaplin has served as a senior member of the management team
of several biopharma companies. During this time, his pioneering research and
development in the area of vascular disrupting strategies resulted in the
identification of Combretastatin A4P (ZYBRESTAT®) (fosbretabulin
tromethamine), a promising anti-cancer therapy currently in advanced clinical
trials. Prior to joining OXiGENE in 2000 as Chief Scientific Officer, Dr.
Chaplin served as Vice President of Oncology for Aventis (now Sanofi), where
he was in charge of all oncology drug discovery and early clinical development
worldwide. He has published over 180 research papers in peer-reviewed
journals, many on the subject of vascular targeting and tumor blood flow.

On behalf of OXiGENE's board, chairman Fred Driscoll said, "We are pleased to
have a person of Dai's caliber and reputation on our management team to lead
the Company and its compounds towards potential commercialization." Mr.
Driscoll continued, "Dai's background in anti-cancer drug development, in
particular his extensive knowledge of ZYBRESTAT, and his involvement with
OXiGENE dating back to 2000 make him a superb choice to lead the Company at
this time."

Dr. Chaplin holds a Ph.D. in Tumor Biology from the University of London. He
received a B.Sc. Honors degree in Chemistry from the University of Essex, and
an M.Sc. in Pharmacology from the University of Southampton.

"I am honored to assume my new role and to lead OXiGENE in its next phase of
development and growth, including the clinical, regulatory and business
development activities that will be required to bring ZYBRESTAT to potential
market commercialization," commented Dr. Chaplin. "I look forward to working
with the team of employees at OXiGENE as we strive to bring new therapeutics
to patients with significant unmet medical needs."

Mr. Driscoll concluded, "We thank Peter Langecker for his leadership over the
past five years during an important and challenging phase of OXiGENE's growth
and development. We wish Peter success in his future endeavors."


OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer.The Company is focused on developing vascular
disrupting agents (VDAs), which are compounds that selectively disrupt
abnormal blood vessels associated with solid tumor survival and
progression.The Company's lead clinical product candidate, ZYBRESTAT^®
(fosbretabulin tromethamine), is in development as a potential treatment for
solid tumors.OXi4503, its second-generation product candidate, is in
development for acute myeloid leukemia (AML).OXiGENE is dedicated to
leveraging its intellectual property and therapeutic development expertise to
bring life-extending and life-enhancing medicines to patients.

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995.Any or all of the
forward-looking statements in this press release, which include the timing of
advancement, outcomes, data and regulatory guidance relative to our clinical
programs and achievement of our business and financing objectives may turn out
to be wrong.Forward-looking statements can be affected by inaccurate
assumptions OXiGENE might make or by known or unknown risks and uncertainties,
including, but not limited to, the inherent risks of drug development,
manufacturing and regulatory review, and the availability of additional
financing to continue development of our programs.Additional information
concerning factors that could cause actual results to materially differ from
those in the forward-looking statements is contained in OXiGENE's reports to
the Securities and Exchange Commission, including OXiGENE's reports on Form
10-K, 10-Q and 8-K.However, OXiGENE undertakes no obligation to publicly
update forward-looking statements, whether because of new information, future
events or otherwise.Please refer to our Annual Report on Form 10-K for the
fiscal year ended December 31, 2013.

CONTACT: Investor and Media Contact:

company logo
Press spacebar to pause and continue. Press esc to stop.